SpineEx filed with the U.S. Securities and Exchange Commission to raise up to US $17MM in an initial public offering to support commercialization of spinal fusion devices. In previous Series A and B financings, the company has raised gross proceeds of $3.3MM to date.
The company has developed the Sagittae® expandable and adjustable cage for lateral lumbar fusion. FDA 510(k) submission occurred in 2Q18, and clearance is expected by year-end.
If cleared, Sagittae would be accompanied by the Scorpio Retractor with disposable accessories and the Herculaes’ Sterilization Container (the latter of which is already approved for sale in China).
SpineEx filed with the U.S. Securities and Exchange Commission to raise up to US $17MM in an initial public offering to support commercialization of spinal fusion devices. In previous Series A and B financings, the company has raised gross proceeds of $3.3MM to date.
The company has developed the Sagittae® expandable and adjustable cage for...
SpineEx filed with the U.S. Securities and Exchange Commission to raise up to US $17MM in an initial public offering to support commercialization of spinal fusion devices. In previous Series A and B financings, the company has raised gross proceeds of $3.3MM to date.
The company has developed the Sagittae® expandable and adjustable cage for lateral lumbar fusion. FDA 510(k) submission occurred in 2Q18, and clearance is expected by year-end.
If cleared, Sagittae would be accompanied by the Scorpio Retractor with disposable accessories and the Herculaes’ Sterilization Container (the latter of which is already approved for sale in China).
Copy to clipboard 
